Patents by Inventor David S. Baker
David S. Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12231414Abstract: Techniques are disclosed relating to multiway communications. In some embodiments, a first electronic device initiates a multiway call between a plurality of electronic devices and exchanges a first secret with a first set of electronic devices participating during a first portion of the multiway call, the first secret being used to encrypt traffic between the first set of electronic devices. The first electronic device receives an indication that first set of participating electronic devices has changed and, in response to the indication, exchanges a second secret with a second set of electronic devices participating during a second portion of the multiway call, the second secret being used to encrypt traffic between the second set of participating electronic devices. In some embodiments, the indication identifies a second electronic device as leaving the multiway call, and the second secret is not exchanged with the second electronic device.Type: GrantFiled: September 20, 2021Date of Patent: February 18, 2025Assignee: Apple Inc.Inventors: Yan Yang, Jin Hyung Park, Joe S. Abuan, Berkat S. Tung, Sean P. Devlin, Vu H. Chiem, Jose A. Lozano Hinojosa, Thomas P. Devanneaux, Vladimir Goupenko, Hsien-Po Shiang, Daniel B. Pollack, Mark M. Xue, David J. Steele, Yu Xing, Ryan W. Baker, Christopher M. Garrido, Ming Jin
-
Patent number: 12220229Abstract: One or more radar sensors can be used to monitor patients in a variety of different environments and embodiments. In one embodiment, radar sensors can be used to monitor a patient's breathing, including monitoring of tidal volume, chest expansion distance, breathing rate, etc. In another embodiment, a patient position can be monitored in a patient bed, which can be used as feedback for control of bladders of a patient bed. Additional embodiments are described herein.Type: GrantFiled: December 14, 2023Date of Patent: February 11, 2025Assignee: Hill-Rom Services, Inc.Inventors: Stacey A. Fitzgibbons, David L. Ribble, Eric R. Meyer, Michael S. Hood, Gregory J. Shannon, Yue Wang, Charles A. Lachenbruch, Steven D. Baker
-
Patent number: 12168017Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: June 1, 2021Date of Patent: December 17, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Publication number: 20240398705Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: July 25, 2024Publication date: December 5, 2024Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Patent number: 12070466Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: June 1, 2021Date of Patent: August 27, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Publication number: 20240165098Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: December 14, 2023Publication date: May 23, 2024Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20240139166Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition comprises a low concentration of an ophthalmic agent for treatment of presbyopia. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water.Type: ApplicationFiled: February 3, 2022Publication date: May 2, 2024Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Patent number: 11896588Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: February 13, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11890277Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: February 6, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11883390Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: January 30, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Publication number: 20230381016Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of a muscarinic antagonist or an ophthalmic agent for treatment of an ophthalmic disorder or condition in a preservative-free ophthalmic formulation. Further disclosed herein include an ophthalmic composition including a low concentration of a muscarinic antagonist or an ophthalmic agent and deuterated water. Also disclosed herein are methods of treating an ophthalmic condition or disease by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 1, 2023Publication date: November 30, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20230092957Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: November 16, 2022Publication date: March 23, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20230091109Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: November 16, 2022Publication date: March 23, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20230093205Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: November 16, 2022Publication date: March 23, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Patent number: 11596625Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 13, 2020Date of Patent: March 7, 2023Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Publication number: 20230041788Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Further disclosed herein is an ophthalmic including a low concentration of an ophthalmic agent and various ratios of water to deuterated water.Type: ApplicationFiled: December 15, 2020Publication date: February 9, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20220409605Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 24, 2022Publication date: December 29, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220409604Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 24, 2022Publication date: December 29, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220409603Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 24, 2022Publication date: December 29, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220378775Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: February 25, 2022Publication date: December 1, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI